Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023380 (lethargy)
 5,697 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The original factor structure of the Aberrant Behavior Checklist was cross-validated with an American sample of 470 persons with moderate to profound mental retardation, including nonambulatory individuals. The results of the factor analysis with varimax rotation essentially replicated previous findings, suggesting that the original five factors (Irritability, Lethargy, Stereotypic Behavior, Hyperactivity, and Inappropriate Speech) could be cross-validated by factor loadings of individual items. The original five scales continue to show high internal consistency. These factors are easily interpretable and should continue to provide valuable research and clinical information.
Am J Ment Retard 1991 Sep
PMID:Cross-validation of the factor structure of the Aberrant Behavior Checklist for persons with mental retardation. 193 Sep 50

This study was conducted to determine whether Depakene could be substituted for Depakote, which would represent a significant financial savings, without sacrificing symptom control or drug tolerance. Over an 8-week period of intensive monitoring, we changed 77 patients from Depakote to Depakene. Results showed no change in seizure control, no adverse upper gastrointestinal side effect, no weight change, no sleep disturbance, no change in aberrant behavior, and no change in appetite. Patients were less less lethargic on Depakene than on Depakote. However, there was some increase in diarrhea, of uncertain cause. Some changes in psychiatric symptoms were also noted. Overall, this drug change was well-tolerated.
Ment Retard 1994 Oct
PMID:Effects on individuals with mental retardation of changing Depakote to Depakene. 798 19

Relations among instruments used in community mental health services for people with developmental disabilities were explored with 284 individuals. Correlation coefficients among the instrument subscales were interpreted in terms of statistical significance and effect size. Of the 157 coefficients, 44% were significant, p < .001, and 35% represented large effects, r > .50. Reiss Screen subscale scores correlated with Irritability, Lethargy, and Hyperactivity on the Aberrant Behavior Checklist (ABC) and with Social Behavior and Disturbing Interpersonal Behavior on the ABS Part II. Stepwise regression analyses predicting Reiss Screen scores from the ABS and ABC resulted in a significant regression, with an overall adjusted R2 of .67. Variance was largely accounted for by two ABS domains and two ABC subscales.
Am J Ment Retard 1999 May
PMID:Correlations among the Reiss Screen, the Adaptive Behavior Scale Part II, and the Aberrant Behavior Checklist. 1034 65

Angelman syndrome is a neurogenetic disorder that is characterized by impairments in neurological, motor, and intellectual functioning. This study compared 27 participants with Angelman syndrome to clinical and community participants with developmental disabilities of mixed etiology to determine whether Angelman syndrome is associated with a distinctive pattern of behavioral functioning. The groups with and without Angelman syndrome were matched on chronological age, gender, and level of intellectual functioning. The dependent measure was parent ratings of maladaptive behavior using the Aberrant Behavior Checklist. The Angelman syndrome group had significantly lower scores on measures of irritability and lethargy. Results contribute to the delineation of a behavior phenotype for the syndrome.
Am J Ment Retard 1999 Jul
PMID:Distinctive pattern of behavioral functioning in Angelman syndrome. 1045 Apr 64